Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

4.345 +0.215 (+5.21%)
Streaming Delayed Price Updated: 1:58 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 490,702
Open 4.130
Bid (Size) 4.340 (2)
Ask (Size) 4.350 (2)
Prev. Close 4.130
Today's Range 4.130 - 4.510
52wk Range 1.080 - 5.000
Shares Outstanding 42,705,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024
GTHX stock results show that G1 Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+39.71%
+39.71%
1 Month
-4.51%
-4.51%
3 Month
+10.00%
+10.00%
6 Month
+224.25%
+224.25%
1 Year
+46.30%
+46.30%

More News

Read More
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
From G1 Therapeutics
Via GlobeNewswire
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
Via Benzinga
Biotech Innovations Paving the Way in Breast Cancer Fight
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today?
Via Benzinga
Exposures Product Safety
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Evercore ISI Is Warming Up to NextEra Energy (NEE) Stock
Via InvestorPlace
UBS Just Upped Its Nvidia (NVDA) Stock Price Target
Via InvestorPlace
Why ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Polished.com (POL) Stock Down 33% Today?
Via InvestorPlace
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
Via InvestorPlace
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Arista Networks Reports Q4 Results, Joins Teradata, Lattice Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
From G1 Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.